查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1576811

非专利药市场：按药物类别、治疗类型、癌症类型、给药途径、最终用户划分 - 2025-2030 年全球预测

Generic Oncology Drugs Market by Drug Class, Therapy Type, Cancer Type, Route Of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年非专利药市值为359.4亿美元，预计2024年将达到387.4亿美元，复合年增长率为7.06%，到2030年将达到579.7亿美元。

非专利药市场范围包括用于癌症治疗的非品牌药物的开拓、生产和分销。这些药物为品牌药物提供了具有成本效益的替代品，并促进更广泛地获得癌症治疗。癌症发生率和医疗费用的增加凸显了对非专利抗癌药物的需求，因此需要负担得起且有效的治疗解决方案。治疗涵盖多种癌症类型，最终用户主要是医院、诊所和癌症治疗中心。关键的成长要素包括癌症发病率上升、重磅抗癌药物的专利到期以及政府鼓励使用学名药的支持措施。药品製造的持续进步和法规环境的改善进一步支持了市场扩张。然而，它们面临着严格的监管要求、潜在的生物等效性问题以及可能影响利润率的品牌药物的激烈竞争等限制。鼓励製药公司专注于先进的药物输送机制、具有成本效益的开发流程和改进配方等创新，以保持竞争优势。此外，您可以透过开拓医疗保健需求不断增长的新兴市场来发现潜在的商机。投资于提高药物疗效、减少副作用和个人化医疗方法的研究可以开闢新的成长途径。儘管面临挑战，但在医疗改革、医疗保健意识不断提高以及对降低医疗成本的日益关注的推动下，非专利药市场仍提供了巨大的机会。提高供应链效率、投资策略伙伴关係以及培养强大的开发平臺的公司很可能会成功。了解市场动态，例如区域需求差异和患者偏好，可以深入了解满足市场需求的策略定位和创新。透过解决限制并利用成长机会，公司可以对肿瘤学领域产生重大影响，同时加快获得基本癌症治疗的机会。

主要市场统计
基准年[2023] 359.4亿美元
预测年份 [2024] 387.4亿美元
预测年份 [2030] 579.7亿美元
复合年增长率（%） 7.06%

市场动态：揭示快速发展的非专利药市场的关键市场洞察

供需的动态交互作用正在改变非专利抗癌药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 由于全球癌症发生率上升，对非专利抗癌药物的需求增加
    • 政府对非专利药抗癌药物研发的措施和资助
    • 不断上涨的医疗成本促使人们转向更具成本效益的学名药
    • 由于越来越多的重磅抗癌药物专利到期，向学名药的转变正在取得进展。
  • 市场限制因素
    • 严格的专利法和智慧财产权问题阻碍学名药进入
    • 供应链脆弱性和原料短缺影响学名药生产
  • 市场机会
    • 透过创新技术改变非专利药市场并改善治疗效果
    • 透过策略伙伴关係和联盟加强学名药研发
    • 监管发展和加速核准途径推动非专利肿瘤学的成长
  • 市场挑战
    • 品牌药的竞争和影响非专利药市场的智慧财产权问题
    • 由于患者认知度低以及对非专利抗癌药物有效性的不信任，市场渗透率下降

波特五力：驾驭非专利药市场的策略工具

波特的五力框架是了解非专利药市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解非专利药市场的外部影响

外部宏观环境因素在塑造非专利药市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解非专利药市场的竞争状况

对非专利药市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 在非专利药市场中的定位矩阵供应商绩效评估

FPNV定位矩阵是评估非专利药市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，非专利药市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对非专利癌症药物市场进行策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着全球癌症发生率的增加，对非专利药的需求也随之增加
      • 政府措施和增加对非专利抗癌药物研发的资助
      • 不断上涨的医疗保健成本推动转向具有成本效益的非专利肿瘤学解决方案
      • 主要抗癌药物的专利到期不断增加，为转向学名药平了道路
    • 抑制因素
      • 严格的专利法和智慧财产权挑战阻碍非专利药的进入
      • 供应链脆弱性和原料短缺影响非专利药生产
    • 机会
      • 创新技术改变非专利药市场并改善治疗效果
      • 策略伙伴关係与合作，加强非专利药的研发
      • 监管进步和加速核准流程推动非专利肿瘤学的成长
    • 任务
      • 品牌药的竞争和智慧财产权问题正在推动非专利药市场的发展
      • 由于患者认知度低以及对非专利抗癌药物有效性的不信任，市场渗透缓慢。
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按药物非专利分類的仿製药市场

  • 烷化剂
    • 含铂类药物
  • 单株抗体
    • 抗CD20
    • 抗CD30
    • 抗HER2
  • 蛋白酪氨酸激酶抑制剂
    • BCR-ABL抑制剂
    • EGFR抑制剂

第七章按治疗类型分類的非专利药市场

  • 辅助性治疗
  • 同步放射线治疗
  • 新辅助辅助性治疗
  • 姑息化疗

第八章按癌症类型非专利药市场

  • 乳癌
  • 大肠直肠癌
  • 肺癌
    • 非小细胞肺癌
    • 小细胞肺癌
  • 摄护腺癌

第九章非专利药市场：依给药途径

  • 可注射的
  • 口服
  • 话题

第 10 章非专利药市场：依最终用户分类

  • 门诊手术中心
  • 医院
  • 肿瘤门诊

第十一章美洲非专利药癌症药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区非专利药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的非专利药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0038

The Generic Oncology Drugs Market was valued at USD 35.94 billion in 2023, expected to reach USD 38.74 billion in 2024, and is projected to grow at a CAGR of 7.06%, to USD 57.97 billion by 2030.

The scope of the generic oncology drugs market encompasses the development, production, and distribution of non-branded medications used for cancer treatment. These drugs offer cost-effective alternatives to branded medications, facilitating broader access to cancer therapies. The necessity for generic oncology drugs is emphasized by the increasing cancer prevalence and healthcare costs, necessitating affordable and effective treatment solutions. Applications span across various cancer types, with end-users primarily including hospitals, clinics, and cancer treatment centers. Key growth influencers include rising cancer incidences, patent expirations of blockbuster oncology drugs, and supportive government initiatives promoting generic drug use. Ongoing advancements in pharmaceutical manufacturing and supportive regulatory environments further bolster market expansion. However, the market faces limitations like stringent regulatory requirements, potential concerns about bioequivalence, and stiff competition from branded drugs, which may affect profit margins. Pharmaceutical companies are recommended to focus on innovations such as advanced drug delivery mechanisms, cost-effective development processes, and enhanced drug formulations to maintain competitive advantage. Additionally, exploring emerging markets with rising healthcare needs can uncover potential opportunities. Investing in research to improve drug efficacy, reduce side effects, and tailor personalized medicine approaches can open new avenues for growth. Despite its challenges, the generic oncology drugs market offers substantial opportunities driven by healthcare reforms, increasing healthcare awareness, and a growing emphasis on reducing medical expenses. Companies that enhance their supply chain efficiency, invest in strategic partnerships, and foster robust research and development pipelines will likely thrive. Understanding market dynamics, including regional demand variations and patient preferences, can provide insights into strategic positioning and innovation tailored to market needs. By addressing limitations and capitalizing on growth opportunities, businesses can significantly impact the oncology landscape while promoting wider access to essential cancer treatment therapies.

KEY MARKET STATISTICS
Base Year [2023] USD 35.94 billion
Estimated Year [2024] USD 38.74 billion
Forecast Year [2030] USD 57.97 billion
CAGR (%) 7.06%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Generic Oncology Drugs Market

The Generic Oncology Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer globally increasing the demand for generic oncology drugs
    • Government initiatives and funding boost for generic cancer drug research and development
    • Escalating healthcare costs drive the shift towards cost-effective generic oncology solutions
    • Increasing patent expiries of blockbuster oncology drugs paving the way for generics transition
  • Market Restraints
    • Stringent patent laws and intellectual property challenges hindering generic oncology drug entry
    • Supply chain vulnerabilities and raw material scarcity affecting generic oncology drug production
  • Market Opportunities
    • Innovative technologies transforming generic oncology drugs market and enhancing therapeutic outcomes
    • Strategic partnerships and collaborations enhancing research and development in generic oncology medications
    • Regulatory advancements and expedited approval pathways driving growth in the generic oncology sector
  • Market Challenges
    • Competition from branded drugs and intellectual property issues impacting the generic oncology drugs market
    • Limited patient awareness and distrust in efficacy of generic oncology drugs reducing market uptake

Porter's Five Forces: A Strategic Tool for Navigating the Generic Oncology Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Generic Oncology Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Generic Oncology Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Generic Oncology Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Generic Oncology Drugs Market

A detailed market share analysis in the Generic Oncology Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Generic Oncology Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Generic Oncology Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Generic Oncology Drugs Market

A strategic analysis of the Generic Oncology Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generic Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Fresenius Kabi AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Generic Oncology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Alkylating Agents, Monoclonal Antibodies, and Tyrosine Kinase Inhibitors. The Alkylating Agents is further studied across Platinum-Based Drugs. The Monoclonal Antibodies is further studied across Anti-CD20, Anti-CD30, and Anti-HER2. The Tyrosine Kinase Inhibitors is further studied across BCR-ABL Inhibitors and EGFR Inhibitors.
  • Based on Therapy Type, market is studied across Adjuvant Therapy, Concurrent Chemoradiation Therapy, Neoadjuvant Therapy, and Palliative Chemotherapy.
  • Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer. The Lung Cancer is further studied across Non-Small Cell Lung Cancer and Small Cell Lung Cancer.
  • Based on Route Of Administration, market is studied across Injectable, Oral, and Topical.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Oncology Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer globally increasing the demand for generic oncology drugs
      • 5.1.1.2. Government initiatives and funding boost for generic cancer drug research and development
      • 5.1.1.3. Escalating healthcare costs drive the shift towards cost-effective generic oncology solutions
      • 5.1.1.4. Increasing patent expiries of blockbuster oncology drugs paving the way for generics transition
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent patent laws and intellectual property challenges hindering generic oncology drug entry
      • 5.1.2.2. Supply chain vulnerabilities and raw material scarcity affecting generic oncology drug production
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative technologies transforming generic oncology drugs market and enhancing therapeutic outcomes
      • 5.1.3.2. Strategic partnerships and collaborations enhancing research and development in generic oncology medications
      • 5.1.3.3. Regulatory advancements and expedited approval pathways driving growth in the generic oncology sector
    • 5.1.4. Challenges
      • 5.1.4.1. Competition from branded drugs and intellectual property issues impacting the generic oncology drugs market
      • 5.1.4.2. Limited patient awareness and distrust in efficacy of generic oncology drugs reducing market uptake
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Generic Oncology Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Alkylating Agents
    • 6.2.1. Platinum-Based Drugs
  • 6.3. Monoclonal Antibodies
    • 6.3.1. Anti-CD20
    • 6.3.2. Anti-CD30
    • 6.3.3. Anti-HER2
  • 6.4. Tyrosine Kinase Inhibitors
    • 6.4.1. BCR-ABL Inhibitors
    • 6.4.2. EGFR Inhibitors

7. Generic Oncology Drugs Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Adjuvant Therapy
  • 7.3. Concurrent Chemoradiation Therapy
  • 7.4. Neoadjuvant Therapy
  • 7.5. Palliative Chemotherapy

8. Generic Oncology Drugs Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Colorectal Cancer
  • 8.4. Lung Cancer
    • 8.4.1. Non-Small Cell Lung Cancer
    • 8.4.2. Small Cell Lung Cancer
  • 8.5. Prostate Cancer

9. Generic Oncology Drugs Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Topical

10. Generic Oncology Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Oncology Clinics

11. Americas Generic Oncology Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Generic Oncology Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Generic Oncology Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Bristol-Myers Squibb Company
  • 6. Celgene Corporation
  • 7. Dr. Reddy's Laboratories Ltd.
  • 8. Eli Lilly and Company
  • 9. Fresenius Kabi AG
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Sun Pharmaceutical Industries Ltd.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GENERIC ONCOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC ONCOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GENERIC ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GENERIC ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENERIC ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC ONCOLOGY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PLATINUM-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ANTI-CD30, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ANTI-HER2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CONCURRENT CHEMORADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY NEOADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PALLIATIVE CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR GENERIC ONCO